International Journal of Electrical and Computer Engineering (IJECE)
Vol. 15, No. 2, April 2025, pp. 2427~2435
ISSN: 2088-8708, DOI: 10.11591/ijece.v15i2.pp2427-2435

Evaluating tumor heterogeneity in oncology with genomic-imaging and cloud-based genomic algorithms

Gurumoorthi Gurulakshmanan[1], Raveendra N. Amarnath[1], Sivaprasad Lebaka[2], Munnangi Koti Reddy[3], Nagarajan Mohankumar[4], Surulivelu Muthumarilakshmi[5], Chelliah Srinivasan[6]

[1]Mphasis, Texas, United State
[2]Department of Electronics and Communication Engineering, Koneru Lakshmaiah Education Foundation, Guntur, India
[3]Department of Electronics and Communication Engineering, Universal College of Engineering and Technology, Guntur, India
[4]Symbiosis Institute of Technology, Nagpur Campus, Symbiosis International (Deemed University), Pune, India
[5]Department of Computer Science and Engineering, Chennai Institute of Technology, Chennai, India
[6]Department of Computer Science and Engineering, Saveetha School of Engineering, Saveetha Institute of Medical and Technical Sciences, Saveetha University, Chennai, India

Article Info

Article history:

Received Mar 15, 2024
Revised Sep 27, 2024
Accepted Oct 23, 2024

Keywords:

Cloud-based genomic algorithms
Genomic-imaging techniques
Oncology
Personalized cancer care
Tumor heterogeneity

ABSTRACT

The goal of this initiative is to rethink how oncology is traditionally practiced by integrating novel approaches to genomic imaging with cloud-based genomic algorithms. The research intends to give a thorough knowledge of cancer biology by focusing on the decoding of tumor heterogeneity as its primary objective. It is possible to get a more nuanced understanding of the intricacy of tumors via the integration of high-resolution imaging tools and sophisticated genetic analysis. It is a pioneering use of cloud computing, which enables the quick analysis of large genomic information. The major goal is to decipher the complex genetic variants that are present inside tumors in order to direct the creation of individualized treatment strategies. This discovery marks a significant step forward, since it successfully bridges the gap between genetics and imaging. Diagnostic accuracy and treatment effectiveness have both been improved. This innovative technique permits real-time analysis, which in turn enables treatment tactics to be adjusted in a timely manner. It makes a significant contribution to the continuous development of oncological research as well as its translation into better clinical outcomes for cancer patients.

Corresponding Author:

Gurumoorthi Gurulakshmanan
Mphasis
Texas, USA
Email: gurumoorthig198@gmail.com

1. INTRODUCTION

The occurrence of several cell types inside a single tumor, a phenomenon known as tumor heterogeneity, presents a substantial problem for oncologists. Because it affects disease development, responsiveness to therapy, and patient outcomes, understanding this variability is critical. The complex molecular and geographical changes within tumors are typically missed by conventional diagnostic approaches [1]. Next-generation sequencing and other high-resolution imaging modalities are examples of genomic-imaging methods that may be used to get a detailed understanding of a tumor's genetic composition and spatial layout. Conventional approaches may overlook subclones and genetic abnormalities, but by studying genomic modifications and the geographic distribution of cells inside a tumor, researchers may find them. Genomic algorithms running in the cloud improve analytical performance by rapidly analyzing

massive datasets [2]. The capacity to share and collaborate on data in real time is a significant benefit of using genomic-imaging methods and cloud-based genomic algorithms. Genomic and imaging data may be safely uploaded and accessed on cloud systems, allowing for more worldwide cooperation and a faster rate of scientific discovery. This kind of streamlined information sharing also aids in the research and development of individualized cancer treatments [3]. The merging of genomic-imaging methods with cloud-based genomic algorithms marks a paradigm leap in the area of cancer. These tools provide scientists and doctor the ability to probe tumor heterogeneity with more depth and accuracy than ever before. By utilizing the analytical power of these revolutionary technologies, oncologists may adapt therapies to specific patients, enhancing therapeutic success while reducing adverse effects [4].

Innovative methods for tracking therapeutic efficacy and anticipating illness relapse have been made possible by the combination of genomic imaging and cloud-based genomic algorithms. Clinicians may maintain a dynamic and individualized approach to patient care by routinely monitoring tumor genetic profiles and spatial changes over the course of therapy [5]. The development of single-cell genomic sequencing technology has led to a deeper comprehension of cellular-level tumor heterogeneity. Cancer development and metastasis may be better understood when tumor cells are studied on a cellular level, since this reveals the intricate details of clonal evolution and intra-tumoral heterogeneity [6]. Beyond primary tumor analysis, genomic-imaging methods and cloud-based genomic algorithms have a wide range of potential applications. Their potential use in the investigation of minimal residual disease (MRD) and circulating tumor cells (CTC) is currently being investigated [7]. Diagnostics, therapy optimization, early detection, and continuous monitoring are just some of the many uses for genomic-imaging methods and cloud-based genomic algorithms in cancer. These tools not only improve our knowledge of tumor heterogeneity but also provide doctors the information they need to perform successful, individualized cancer treatment [8].

Unraveling the complexity of cancer immunotherapy is a field where the combination of genomic-imaging methods and cloud-based genomic algorithms has enormous promise beyond clinical applications. In certain cases of cancer, immunotherapies including immune checkpoint inhibitors and chimeric antigen receptor (CAR-T) cell treatments have shown to be quite effective. Due to tumor heterogeneity, their efficacy varies substantially across patients. By studying the tumor's genetic and geographical properties, researchers may find particular immune evasion methods exploited by cancer cells [9]. Collaborations between researchers from different fields have proliferated since genomic-imaging methods were integrated with cloud-based platforms. To understand the complex relationship between genetic mutations, physical space, and patient outcomes, researchers from several disciplines, including genomics, radiomics, bioinformatics, and data science, must work together [10]. Cancer research and therapy have become more accessible thanks to the widespread availability of genetic data via cloud-based systems. By removing physical boundaries and creating a worldwide network of researchers, large genomic and imaging datasets are now accessible to scientists everywhere [11]. There has been a significant advancement in the field of cancer thanks to the combination of genomic imaging methods and genomic algorithms hosted on the cloud. These tools not only shed light on the complex terrain of tumor heterogeneity, but also drive novel insights, individualized therapies, and team-based research. By incorporating these innovative strategies, the oncology community may make cancer more of a manageable illness for patients and change the course of cancer treatment for the better [12].

Cancer prevention and public health programs are also benefiting from the advances made possible by genomic-imaging methods and cloud-based genomic algorithms. Researchers may learn more about the genetic predispositions and risk factors linked with different forms of cancer by examining large-scale genomic data from varied populations. Through this evidence-based strategy, policymakers are better able to reduce the cancer burden on society by allocating resources effectively, implementing focused interventions, and increasing awareness of preventative measures [13]. By identifying those at greatest risk, we may create individualized screening programs and lifestyle treatments to reduce their likelihood of developing the disease. The incorporation of cloud-based analytics into public health systems also permits continuous tracking of cancer rates and tendencies. These methods are also helping researchers understand how cancer patients develop resistance to treatment [14]. To create novel treatment strategies, such as combination therapies that sidestep drug resistance pathways, a molecular understanding of these processes is essential. Cloud-based genomic systems serve a vital role in gathering and processing vast information from clinical trials and patient cohorts, allowing the development of predictive biomarkers of treatment response and resistance [15].

Oncology is always changing, making tumor heterogeneity a major concern. Tumor heterogeneity—the variation in genetic and phenotypic traits within a tumor—makes therapy difficult. Recently developed genomic-imaging tools and cloud-based genomic algorithms may help evaluate this heterogeneity. Traditional approaches for measuring tumor heterogeneity miss many of the complex genetic changes that

drive cancer growth. Next-generation sequencing (NGS) and high-resolution imaging modalities reveal the tumor's genomic landscape and spatial structure. Researchers may uncover genetic mutations, epigenetic alterations, and microenvironmental variables using these methods, revealing the tumor's complexity. Cloud-based genomic algorithms are essential for processing these methods' massive data sets. These methods use cloud computing to quickly and correctly handle large datasets. These advances have promise, but obstacles remain. Standardizing genomic-imaging methodologies, cloud data privacy and security, and interpretable algorithms are urgent issues. Integrating genomes, proteomics, and metabolomics data requires new solutions.

Tumor heterogeneity has prompted oncology researchers to use cutting-edge technology. NGS and high-resolution imaging have transformed cancer biology. These methods reveal the mutations, epigenetic changes, and microenvironmental variables that cause tumor heterogeneity by diving into tumor genetics. In parallel, cloud-based genomic algorithms enable rapid analysis of large and complicated genomic datasets. These methods integrate multi-omics data using cloud computing, helping researchers find previously undiscovered patterns and relationships. Researchers may discover new biomarkers and therapeutic targets by combining resources and ability to decipher these complex datasets. Standardizing genomic-imaging procedures is a major advance. Clinicians may create tailored treatment plans by deciphering complex genetic patterns. Interpretable algorithms let healthcare practitioners make educated choices for patients by connecting raw data to clinical application.

A new era of patient involvement and agency are ushered by the combination of genomic imaging and cloud computing. Patients may now access their genetic and imaging data in ways never before possible, giving them a voice in their care decisions. More individualized and patient-centered cancer treatment is the result of an open approach, which improves communication between patients and doctors, increases trust, and encourages collaborative decision-making [16]. The information accessible to researchers and clinicians may be improved by the addition of patient-generated data such as lifestyle choices and treatment preferences to genetic databases. An all-encompassing approach to cancer treatment and survival is ensured by gaining a more thorough understanding of the disease through the eyes of patients and using that knowledge to shape the design of supportive care interventions [17]. The field of oncology is undergoing a radical transformation as cutting-edge genomic-imaging methods and cloud-based genomic algorithms are brought together. These technologies have far-reaching implications throughout the whole cancer care continuum, from expanding precision medicine and collaborative research to improving cancer prevention measures and patient involvement [18].

Cancer clinical trials and drug development are undergoing a sea change with the combination of genomic-imaging methods and cloud-based genomic algorithms. The complexities of tumor heterogeneity are typically overlooked in conventional clinical trial designs, resulting to inferior results in patient cohorts. Comprehensive genomic sequencing and high-resolution imaging have allowed for the stratification of treatment trials according to the presence or absence of certain genetic changes and spatial patterns inside malignancies [19]. Patients are more likely to benefit from experimental therapies if they are included in studies aimed at their specific genetic risk factors. Adaptive trial designs that may fast modify depending on new genetic discoveries are made possible by cloud-based tools that permit real-time data processing. Improved patient access to cutting-edge medications is a direct result of this adaptability, which boosts the efficacy of clinical trials by speeding up the translation of promising therapies from the lab to the clinic [20].

Data integrity and security in cancer research are being completely transformed by the combination of blockchain technology, genomic-imaging tools, and cloud-based platforms. Blockchain's distributed and tamper-proof nature assures genetic and imaging data is immutable, shielding it from prying eyes. This protected setting promotes confidence among participants, which in turn fuels unprecedented levels of data exchange and cooperation [21]. Scientists may work together without worrying about compromising the security of their data since they can trust that it will be safe. Smart contracts made possible by the blockchain might dramatically alter the manner in which institutions and individual researchers work together, pool resources, and contribute to large-scale international genomic efforts. This novel method not only protects patients' privacy but also lays a solid groundwork for more secure and ethical data-driven cancer research in the future [22].

Education and training in the medical field are evolving as aortic regurgitation (AR) and therapeutic virtual reality (VR) technology are combined with genomic imaging methods. Now, doctors can dive deep into 3D tumor models and explore their genetic and spatial complexities without leaving their desks. Multidisciplinary tumor boards and global collaboration are made easier by augmented and virtual reality technology [23]. Experts from all across the world, including oncologists, geneticists, radiologists, and researchers, may work together on virtual platforms to evaluate complicated genomic and imaging data. Patients will benefit from improved diagnostic accuracy and individualized treatment strategies thanks to the digital transformation of medical education that is providing healthcare professionals with the knowledge and skills necessary to effectively leverage genomic-imaging techniques and cloud-based algorithms [24]. Cancer

research, diagnosis, treatment, and education are all being profoundly altered by the revolutionary confluence of genomic-imaging methods, cloud-based genomic algorithms, blockchain technology, and augmented or virtual reality breakthroughs. The future is unquestionably better and healthier for cancer patients and their families throughout the globe if we embrace these developments with excitement and a collaborative attitude [25]. The detailed study is followed with the proposed system, results and discussion, conclusion. K-mean clustering examine the influence of different image clusters and each cluster is separate left and right portions. Moreover, the mutual symmetry measure is useful to evaluate the cluster which contains the tumor [26]. An automatic brain tumor detection system applies the body actions of the brain to distinguish brain tumors [27]. Incorporating internet of things (IoT) and geographic information systems (GIS) techs to enhance the quality of observing system; as a result, improve the sensing field process [28]. Raspberry Pi-enabled wearable sensors to observes the health [29]. IoT-enabled medication safety undertakes a significant issue in the healthcare by taking jointly the technical growths, and patient-centered treatment [30].

2. PROPOSED SYSTEM

2.1. Unlocking the potential of genomic-imaging techniques and cloud-based genomic algorithms in understanding tumor heterogeneity in oncology

Understanding the intricate landscape of tumor heterogeneity is crucial in the field of oncology, as it paves the way for personalized and effective cancer treatments. Genomic-imaging techniques and cloud-based genomic algorithms have emerged as revolutionary tools, offering unprecedented insights into the complex genomic variations within tumors. Genomic-imaging techniques, such as NGS and high-resolution imaging, play a pivotal role in unraveling the genomic diversity of tumors. Figure 1 indicates that intra-tumoral heterogeneity is a diverse population of sub-clones with variable genetics, epigenetics, metabolism, tumor behavior, and treatment response. Distinct tumors in the same patient have distinct genetic and non-genetic alterations (indicated by different colors), which impacts therapy response. Precision medicine requires inter-tumoral heterogeneity. Next-generation sequencing revealed genetic and functional differences between tumor populations or subclones. Some heterogenous tumor sub-clones become drug-resistant or survive better after treatment, causing recurrence.



Figure 1. Multiple degrees of cancer heterogeneity impact patient outcomes

2.2. Revolutionizing oncology: exploring the impact, applications, and advantages of evaluating tumor heterogeneity with genomic-imaging techniques and cloud-based genomic algorithms

The advent of genomic-imaging and cloud-based genomic algorithms has revolutionized oncology and tumor heterogeneity. Granular tumor heterogeneity assessment alters cancer research and treatment. Tumor heterogeneity assessment utilizing genomic imaging and cloud-based genomic algorithms is significant. Individualized medicine is a major contribution. By studying tumors' genetics and anatomy, doctors can improve treatment and reduce side effects. In fact, in recent decades, combination therapy techniques that target cancer cells via several pathways have emerged to overcome innate acquired resistance. Stepwise somatic cellular mutations cause cancer that has many sub-clonal populations, as shown in Figure 2.



Figure 2. Tumor heterogeneity and clonal evolution

3. RESULTS AND DISCUSSION

3.1. Advancing oncological research: sequence alignment algorithms in evaluating tumor heterogeneity through genomic-imaging techniques and cloud-based genomic algorithms

Genomic technology has changed oncology by exposing tumor genetics. Cancer researchers struggle to understand tumor heterogeneity—the variety in cancer cells within a tumor or across numerous tumors. Complex genomic and imaging data integration requires advanced methodologies. Sequence alignment techniques show tumor heterogeneity, enabling personalized therapy. This study uses genomic-imaging and cloud-based genomic algorithms to show the usefulness of sequence alignment algorithms in oncology tumor heterogeneity research. Cancer's unpredictability complicates diagnosis and treatment. Genomic and imaging data are needed to comprehend this complexity. Tumor anatomy and geographic distribution are shown by magnetic resonance imaging (MRI) and polyethylene terephthalate (PET), whereas genetics are revealed by NGS. Integrating several data sources needs strong computational methods, notably sequence alignment techniques, to compare deoxyribonucleic acid (DNA) sequences and detect tumor-promoting changes. Basic local alignment search tool (BLAST), Smith-Waterman, and Needleman-Wunsch are fundamental bioinformatics sequence alignment methods. Researchers use algorithms to analyze nucleotide or amino acid sequences to find gene or protein similarities, differences, and evolutionary relationships. Patients exhibit intratumor, inter-metastatic, and intra-metastatic heterogeneity. Intra-tumor heterogeneity is a single tumor mass with numerous cell subpopulations affected differently by treatment. Different tumor heterogeneities make disease treatment and acquired resistance problematic is shown in Figure 3.

Figure 4 indicates that sequence alignment algorithms processed 150,000 sequences and variant calling algorithms 120,000 variations in 2021. Genomic-imaging techniques analyzed 75,000 pictures and cloud-based genomic algorithms 90,000 cases. Sequence alignment processed 180,000 sequences, variant calling 135,000 variants, genomic-imaging techniques 85,000 images, and cloud-based genomic algorithms 95,000 data sets by 2022. Sequence alignment algorithms processed 200,000 sequences, variant calling algorithms 150,000 variants, genomic-imaging techniques 95,000 images, and cloud-based genomic algorithms 100,000 data sets in 2023.



Figure 3. Examples of tumor heterogeneity across and among patients



Figure 4. Evolution of sequence alignment and variant calling algorithms in oncology: a genomic perspective

Table 1 shows how genomic-imaging and cloud-based algorithms have transformed cancer research and therapy. By accurately mapping DNA sequences, sequence alignment algorithms help researchers uncover genetic changes using variant calling algorithms. Precision medicine and disease research need these algorithms' high sensitivity and specificity. They also aid genomic studies and comparative genomics by processing enormous data sets. These methods help us comprehend tumor heterogeneity in oncology. Oncology advances with real-time data and visualization for tailored cancer therapies and prognosis assessments.

Table 1. Advancements in oncology: genomic-imaging techniques and cloud-based algorithms

Role	Benefit	Advantages	Applications
Sequence alignment algorithms	DNA sequence mapping accuracy	Effectively handles big datasets	Comparative genomics, genomic study
Variant calling algorithms	Genetic variation identification	Excellent sensitivity and specificity	Precision medicine, illness research
Evaluating tumor heterogeneity in oncology	Comprehensive tumor variety knowledge	Analytics and visualization in real time	Prognosis, personalized cancer therapy

3.2. Unraveling tumor heterogeneity: variant calling algorithms in oncology through genomic-imaging techniques and cloud-based genomic algorithms

Oncology's ever-changing environment requires tumor heterogeneity understanding. Tumor genetic diversity requires advanced approaches to comprehend. Pioneering tumor heterogeneity discoveries have been made using genomic and imaging approaches and cloud-based genomic algorithms. Variant calling algorithms, the unsung heroes of oncological tumor research, underlie this novel technology. Oncological research relies on variant calling to discover tumor genomic alterations. By overcoming ethical difficulties, these technologies secure patient data and speed research. Cloud-based genomic algorithms let researchers swiftly and comprehensively grasp tumor heterogeneity. The comparison is shown in Table 2. These algorithms precisely align tumor DNA, making them vital in oncology. Their genomic-imaging integration provides perfect alignment for mutation and structural variation detection. Cloud systems provide real-time analysis of large-scale sequencing data, improving efficiency. These algorithms are necessary for tumor genome decoding, mutation, copy-number variation (CNV), and rearrangement detection. Integrating genomic-imaging technology gives complete tumor heterogeneity insights. Cloud-based tools provide in-depth analysis of enormous information, helping physicians choose tailored cancer therapies.

Table 2. Comparative analysis of sequence alignment and variant calling algorithms in oncology: unraveling tumor heterogeneity with genomic-imaging techniques and cloud-based solutions

Category	Sequence alignment algorithms	Variant calling algorithms
Overview	1. To compare DNA/RNA sequences, sequence alignment methods align them. 2. These are essential to genetics and medical diagnosis.	1. Mutations and single nucleotide polymorphisms (SNPs) in DNA sequences are detected using variant calling techniques. 2. These are essential for tumor heterogeneity and tailored treatment.
Application in Oncology	1. These methods accurately match tumor DNA sequences, allowing researchers to find mutations, structural changes, and fusion genes for cancer diagnosis and therapy.	1. Variant calling techniques reveal mutations, CNVs, and rearrangements in tumor genomes, helping explain tumor heterogeneity and evolution.
Integration with genomic-imaging and cloud-based platforms	1. Sequence alignment techniques assist genomic-imaging technologies in data alignment. 2. Scalable cloud systems analyze huge sequencing data in real time.	1. Genomic-imaging technologies leverage cloud-based variant calling techniques for large datasets. 2. This integration enables precise tumor heterogeneity analysis for clinical concerns.

We understand tumor heterogeneity in oncology, integrative genomic analysis is essential. Sequence alignment algorithms align sequences with 98.2%, 97.5%, and 96.8% precision. Genomic variant calling algorithms systematically identify 1320, 1288, and 1355 tumor genome variants. Cloud-based genomic algorithms rapidly process 4.5, 4.2, and 4.7 TB of data. By measuring tumor heterogeneity, this multi-dimensional method allows researchers to explore cancer's complex topography and develop individualized treatments. Oncology is transformed by integrated genomic analysis' accuracy and scalability.

4. CONCLUSION

The complex landscape of tumor heterogeneity in oncology has been shed light upon thanks to the fusion of genomic-imaging approaches and cloud-based genomic algorithms. This ground-breaking method has improved the accuracy and specificity of cancer therapies by providing a better knowledge of genetic changes inside tumors. Improved diagnostic precision and therapy options have resulted from the combination of high-resolution imaging and cutting-edge genetic analysis of tumors. Real-time analysis, made possible by the simplified processing of large genomic information utilizing cloud computing, allows rapid modifications to therapeutic treatments. The implications of this discovery for the future of cancer therapy and patient outcomes are enormous. Exploring the limits of precision medicine in cancer necessitates further study into the best ways to integrate genetic and imaging technology. Future research should attempt to increase the scalability and accessibility of cloud-based genomic algorithms, encouraging their wider implementation in clinical settings. Exploring how artificial intelligence and machine learning may be used to make sense of complicated genomic and imaging data will pave the way for novel cancer studies. Research that follows patients over time to see how individualized therapies affect their health and happiness over time would be really helpful. It is imperative that doctors, geneticists, and computational scientists work together to further the science and implement these findings into practical advances in cancer therapy.

REFERENCES

[1] S. Aneja, A. Avesta, H. Xu, and L. O. Machado, "Clinical informatics approaches to facilitate cancer data sharing," *Yearbook of Medical Informatics*, vol. 32, no. 1, pp. 104–110, Aug. 2023, doi: 10.1055/s-0043-1768721.

[2] Q. W. Zhang *et al.*, "Personalized radiomics signature to screen for KIT-11 mutation genotypes among patients with gastrointestinal stromal tumors: a retrospective multicenter study," *Journal of Translational Medicine*, vol. 21, no. 1, p. 726, Oct. 2023, doi: 10.1186/s12967-023-04520-w.

[3] S. Choen, M. S. Kent, A. J. Chaudhari, S. R. Cherry, A. Krtolica, and A. L. Zwingenberger, "Kinetic evaluation of the hypoxia radiotracers [18F]FMISO and [18F]FAZA in dogs with spontaneous tumors using dynamic PET/CT imaging," *Nuclear Medicine and Molecular Imaging*, vol. 57, no. 1, pp. 16–25, Feb. 2023, doi: 10.1007/s13139-022-00780-4.

[4] K. E. Link *et al.*, "Longitudinal deep neural networks for assessing metastatic brain cancer on a large open benchmark," *Nature Communications*, vol. 15. pp. 1–10, Jan. 11, 2024, doi: 10.21203/rs.3.rs-2444113/v1.

[5] S. Ning *et al.*, "Imaging genetic association analysis of triple-negative breast cancer based on the integration of prior sample information," *Frontiers in Genetics*, vol. 14, Feb. 2023, doi: 10.3389/fgene.2023.1090847.

[6] U. K. Hisan and M. M. Amri, "Recommendation of precision medicine application in Indonesia from multiple perspective: a review," *International Journal of Public Health Science*, vol. 12, no. 1, pp. 225–238, Mar. 2023, doi: 10.11591/ijphs.v12i1.22010.

[7] V. A. Arrieta *et al.*, "Immune checkpoint blockade in glioblastoma: from tumor heterogeneity to personalized treatment," *Journal of Clinical Investigation*, vol. 133, no. 2, Jan. 2023, doi: 10.1172/JCI163447.

[8] M. Mijiti *et al.*, "CRISPR-cas9 screening identified lethal genes enriched in Hippo kinase pathway and of predictive significance in primary low-grade glioma," *Molecular Medicine*, vol. 29, no. 1, p. 64, May 2023, doi: 10.1186/s10020-023-00652-3.

[9] R. K. Vanakamamidi, N. Abirami, C. Sasi Kumar, L. Ramalingam, S. Priyanka, and S. Murugan, "IoT security based on machine learning," in *2023 2nd International Conference on Smart Technologies for Smart Nation, SmartTechCon 2023*, Aug. 2023, pp. 683–687, doi: 10.1109/SmartTechCon57526.2023.10391727.

[10] M. A. Al-Hamaly, L. T. Turner, A. Rivera-Martinez, A. Rodriguez, and J. S. Blackburn, "Zebrafish cancer avatars: a translational platform for analyzing tumor heterogeneity and predicting patient outcomes," *International Journal of Molecular Sciences*, vol. 24, no. 3, p. 2288, Jan. 2023, doi: 10.3390/ijms24032288.

[11] D. Ventura *et al.*, "Radiomics of tumor heterogeneity in 18F-FDG-PET-CT for predicting response to immune checkpoint inhibition in Therapy-Naïve patients with advanced non-small-cell lung cancer," *Cancers*, vol. 15, no. 8, p. 2297, Apr. 2023, doi: 10.3390/cancers15082297.

[12] R. Yang, S. Zheng, and R. Dong, "Circulating tumor cells in neuroblastoma: current status and future perspectives," *Cancer Medicine*, vol. 12, no. 1, pp. 7–19, Jan. 2023, doi: 10.1002/cam4.4893.

[13] E. Berrino *et al.*, "Unique patterns of heterogeneous mismatch repair protein expression in colorectal cancer unveil different degrees of tumor mutational burden and distinct tumor microenvironment features," *Modern Pathology*, vol. 36, no. 2, p. 100012, Feb. 2023, doi: 10.1016/j.modpat.2022.100012.

[14] Q. Huang *et al.*, "Intraindividual tumor heterogeneity of mismatch repair status in metastatic colorectal cancer," *Applied Immunohistochemistry and Molecular Morphology*, vol. 31, no. 2, pp. 84–93, Feb. 2023, doi: 10.1097/PAI.0000000000001089.

[15] E. Irawan *et al.*, "Identification of tumor infiltrating lymphocyte CD8 in Indonesian colorectal cancer population: a cross-sectional study," *Bali Medical Journal*, vol. 12, no. 2, pp. 1781–1785, 2023, doi: 10.15562/bmj.v12i2.4520.

[16] M. D. A. Hasan, K. Balasubadra, G. Vadivel, N. Arunfred, M. V. Ishwarya, and S. Murugan, "IoT-driven image recognition for microplastic analysis in water systems using convolutional neural networks," in *2024 2nd International Conference on Computer, Communication and Control, IC4 2024*, Feb. 2024, pp. 1–6, doi: 10.1109/IC457434.2024.10486490.

[17] B. Ng *et al.*, "Breast cancer incidence in Yogyakarta, Indonesia from 2008–2019: a cross-sectional study using trend analysis and geographical information system," *PLoS ONE*, vol. 18, no. 7 JULY, p. e0288073, Jul. 2023, doi: 10.1371/journal.pone.0288073.

[18] N. Rahadiani, M. Stephanie, A. G. Perkasa, D. R. Handjari, and E. Krisnuhoni, "P53 expression is associated with tumor stage, grade and subtype in patients with hepatocellular carcinoma," *Molecular and Clinical Oncology*, vol. 19, no. 1, p. 54, May 2023, doi: 10.3892/mco.2023.2650.
[19] R. Rosaudyn, F. Mutiani, I. Yuliati, and B. R. Indraprasta, "Prognostic value of neutrophil-to-lymphocyte ratio and fibrinogen levels in ovarian cancer," *Medical Journal of Indonesia*, vol. 32, no. 2, pp. 86–97, Oct. 2023, doi: 10.13181/mji.oa.236880.
[20] F. Halim, Y. Azhar, S. Suwarman, E. J. Wahjoepramono, and B. Hernowo, "Positive p53 expression is associated with primary endocrine therapy resistance in locally advanced stage luminal b her2-negative breast cancer patients: a cross-sectional study in Indonesia," *Diagnostics*, vol. 13, no. 11, p. 1838, May 2023, doi: 10.3390/diagnostics13111838.
[21] M. S. N. Gautama, H. Haryani, and T. W. Huang, "Efficacy of smartphone-based virtual reality relaxation in providing comfort to patients with cancer undergoing chemotherapy in oncology outpatient setting in Indonesia: Protocol for a randomised controlled trial," *BMJ Open*, vol. 13, no. 7, p. e074506, Jul. 2023, doi: 10.1136/bmjopen-2023-074506.
[22] M. Amru *et al.*, "Network intrusion detection system by applying ensemble model for smart home," *International Journal of Electrical and Computer Engineering*, vol. 14, no. 3, pp. 3485–3494, Jun. 2024, doi: 10.11591/ijece.v14i3.pp3485-3494.
[23] T. E. Novianti, Q. Rachmah, and M. Adriani, "The effect of low-fiber diets on colorectal cancer incidence in Southeast and East Asia: systematic review and meta-analysis," *Indonesian Journal of Public Health*, vol. 18, no. 2, pp. 353–365, Aug. 2023, doi: 10.20473/Ijph.v18i2.2023.353-365.
[24] L. K. D. Cabral *et al.*, "Network analysis for the discovery of common oncogenic biomarkers in liver cancer experimental models," *Biomedicines*, vol. 11, no. 2, p. 342, Jan. 2023, doi: 10.3390/biomedicines11020342.
[25] M. J. Kumar, S. Mishra, E. G. Reddy, M. Rajmohan, S. Murugan, and N. A. Vignesh, "Bayesian decision model based reliable route formation in internet of things," *Indonesian Journal of Electrical Engineering and Computer Science*, vol. 34, no. 3, pp. 1665–1673, Jun. 2024, doi: 10.11591/ijeecs.v34.i3.pp1665-1673.
[26] F. S. Baji, S. B. Abdullah, and F. S. Abdulsattar, "K-mean clustering and local binary pattern techniques for automatic brain tumor detection," *Bulletin of Electrical Engineering and Informatics*, vol. 12, no. 3, pp. 1586–1594, Jun. 2023, doi: 10.11591/eei.v12i3.4404.
[27] M. L. Rahman, A. W. Reza, and S. I. Shabuj, "An internet of things-based automatic brain tumor detection system," *Indonesian Journal of Electrical Engineering and Computer Science*, vol. 25, no. 1, pp. 214–222, Jan. 2022, doi: 10.11591/ijeecs.v25.i1.pp214-222.
[28] V. G. Sivakumar, V. V. Baskar, M. Vadivel, S. P. Vimal, and S. Murugan, "IoT and GIS integration for real-time monitoring of soil health and nutrient status," in *International Conference on Self Sustainable Artificial Intelligence Systems, ICSSAS 2023 - Proceedings*, 2023, pp. 1265–1270, doi: 10.1109/ICSSAS57918.2023.10331694.
[29] K. Karthika, S. Dhanalakshmi, S. M. Murthy, N. Mishra, S. Sasikala, and S. Murugan, "Raspberry Pi-enabled wearable sensors for personal health tracking and analysis," in *International Conference on Self Sustainable Artificial Intelligence Systems, ICSSAS 2023 - Proceedings*, Oct. 2023, pp. 1254–1259, doi: 10.1109/ICSSAS57918.2023.10331909.
[30] S. Selvarasu, K. Bashkaran, K. Radhika, S. Valarmathy, and S. Murugan, "IoT-enabled medication safety: real-time temperature and storage monitoring for enhanced medication quality in hospitals," in *2nd International Conference on Automation, Computing and Renewable Systems, ICACRS 2023 - Proceedings*, Dec. 2023, pp. 256–261, doi: 10.1109/ICACRS58579.2023.10405212.

BIOGRAPHIES OF AUTHORS

Gurumoorthi Gurulakshmanan is an experienced technical project manager with 15+ years of experience leading multiple large-scale programs, developing strategic vision and goals, driving digital transformation to the cloud and evolving IT delivery methodologies. Proven record of championing solutions to solve highly-complex business problems and delivering on digital transformation with cloud-native solutions. Strong collaborator, partnered closely with key stakeholders to drive strategic approach to maximize growth. Influential and effective cross-functional team and people leader with a focus on cost optimization initiatives. A thought leader in operational efficiency and team building to ensure the best customer experience with a DevOps mindset. Demonstrated history of working in the industry as an engineer, technical manager and Sr. program manager. He can be contacted at email: gurumoorthig198@gmail.com.

Raveendra N. Amarnath is an accomplished project manager at Mphasis, boasting over 18 years of invaluable experience in the software industry. Residing in Dallas, Texas, his expertise shines in the realm of testing solutions, emphasizing reliability and automation. His career is characterized by his relentless pursuit of excellence in testing and his dedication to managing complex projects with precision. His extensive technical knowledge and leadership skills have made him an invaluable asset in the world of software and data management. In his current role, Raveendra spearheads the management of one of North America's most ambitious data migration projects, involving the seamless transition of data from Teradata to Google Cloud. His extensive background spans across diverse domains, including Airlines, Banking and Investment, Non-Life Insurance, Pharmacovigilance, and the UK Government. Raveendra's technical prowess encompasses data engineering, extract, transform, load (ETL), informatica, Teradata, big query, as well as mastery in JAVA and .NET applications. He is equally well-versed in the intricacies of SOAP and REST APIs. He can be contacted at email: raveendra.techie@gmail.com.

Sivaprasad Lebaka working as an assistant professor in the Electronics and Communication Engineering Department at the Koneru Lakshmaiah Education Foundation located in Vaddeswaram, Guntur District, Andhra Pradesh. He has 13 years of teaching experience and pursuing his Ph.D. in electronics and communication engineering from VTU, Belagavi, India. He is specialized in leveraging machine learning (ML) techniques for image processing applications. Throughout her academic career, he has contributed 14 papers to international journals in his field of expertise. He is an active life member of the Indian Society for Technical Education (ISTE), Institution of Electronics and Telecommunication Engineers (IETE) and holds memberships in International Association of Engineers (IAENG) and the International Association of Computer Science and Information Technology (IACSIT). Additionally, he has participated in numerous training sessions and conferences that focus on advancements in signal and image processing. He can be contacted at email: sivaprasadlebaka@gmail.com.

Munnangi Koti Reddy received the Ph.D. degree in ECE from KU, Raipur in January 2019 and the M.Tech. degree in VLSI design from the Viganan University, AP, India, in 2011 and the B.Tech. degree in electronics and communication engineering from JNTU Kakinada, A.P, India, in 2009 and Diploma in ECE from Gudlavalleru Engineering College. His research interests include Wireless Communications, Embedded systems and VLSI design. He has published 12 research papers in various International Journals and conferences. Presently he is working as associate professor in the Department of ECE, Universal College of Engineering and Technology, Guntur, Andhra Pradesh, 522438. He can be contacted at email: kotiucet@gmail.com.

Nagarajan Mohankumar was born in India in 1978. He received his B.E. Degree from Bharathiyar University, Tamil Nadu, India in 2000 and M.E. and Ph.D. degree from Jadavpur University, Kolkata in 2004 and 2010. He joined the Nano Device Simulation Laboratory in 2007 and worked as a senior research fellow under CSIR direct Scheme till September 2009. Later he joined SKP Engineering College as a professor to develop research activities in the field of VLSI and NANO technology. He is currently working as a research professor at Symbiosis Institute of Technology, Nagpur Campus, Symbiosis (International) Deemed University, Pune, India. He is a senior member of IEEE. He has about 85 International journal publications in reputed journals and about 50 international conference proceedings. He received the carrier award for young teachers (CAYT) from AICTE, New Delhi in the year of 2012-2014. His research interest includes modeling and simulation study of HEMTs, optimization of devices for RF applications and characterization of advanced HEMT architecture, terahertz electronics, high frequency imaging, sensors and communication. He can be contacted at email: nmkprofessor@gmail.com.

Surulivelu Muthumarilakshmi is an associate professor in computer science and engineering at Chennai Institute of Technology, Kundrathur. With over 13 years of teaching experience, my primary focus revolves around computer networks. She is particularly interested in investigating network protocols, security measures, and ways to optimize network performance. She passion lies in researching and publishing articles that delve into these areas, aiming to enhance our understanding of robust network systems and contribute valuable insights to the academic community. She can be contacted at: muthu3041974@gmail.com.

Chelliah Srinivasan is an adjunct professor at Department of Computer Science and Engineering, Saveetha School of Engineering, Saveetha Institute of Medical and Technical Sciences: Chennai, Tamil Nadu, India. His research areas include image processing, signal processing, pattern recognition and deep learning. He published a book ‘Digital Image Processing’ by Dipti Press OPC Private Limited. He published his research articles in many international and national conferences and journals. He can be contacted at email: srinivasanchelliah@gmail.com.